DNA repair is a crucial factor in maintaining a low steadystate level of oxidative DNA damage and protecting us from cancer. Cancer case-control studies, using indirect assays in which chromosome breakage in lymphocytes is taken as a measure of failure to repair DNA, indicate an association between poor repair and cancer risk, but casecontrol studies can be misleading. Surprisingly little is known of the variations in repair capacity within healthy human populations. It is likely that differences in repair enzyme activity result from genetic polymorphisms in repair genes, which have been shown, in some cases, to be linked to cancer. There is a need for prospective studies, in which genotype is analysed (for a range of repair and related genes) and repair activity measured before cancer has developed. Using a new method to measure repair in an extract of lymphocytes, based on a modification of the comet assay, we are seeking answers to the following questions: what is the normal range of repair activities in healthy humans; do differences in repair capacity correlate with genetic variations; is low repair capacity associated with a high risk of cancer; how important is DNA repair rate in determining the steady-state level of damage; what is the extent of intra-individual variation; is repair modulated by environmental factors or induced by damage; are there differences in repair capacity between men and women; what is the association of DNA repair with ageing?
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Oxidative DNA damage and repair Oxidative damage to DNA is readily measured in human cells, but estimates of the background level of the most abundant (and potentially mutagenic) oxidized base, 8-oxoguanine, have varied over orders of magnitude (Collins et al., 1997) . It now seems clear, and is becoming widely accepted, that DNA oxidation occurs during sample preparation for analysis by HPLC or GC-MS (ESCODD, 2002; Gedik et al., 2002) . Recent determinations with methods free of this artefact indicate a true level of damage of~1-5 8-oxoguanines/10 6 guanines (Gedik et al., 2002; ESCODD, in press) . This relatively low level of damage reflects the presence in all cells of antioxidant defences and DNA repair. Reactive oxygen species abound, as a by-product of respiration, but most are removed by antioxidant enzymes or scavengers such as glutathione (as well as by dietary antioxidants such as vitamin C, carotenoids, flavonoids, etc.). The damage measured is in a dynamic steadystate; the input (regulated by antioxidants) is balanced by the output, i.e. DNA repair.
Small alterations to bases, including oxidation and alkylation, are mainly repaired by the pathway known as base excision repair (BER). A lesion-specific glycosylase removes the base and the resulting apurinic/apyrimidinic (AP) site is converted to a break. A small gap (one or a few nucleotides) is filled in by DNA polymerase plus ligase (Evans et al., 2000) . BER is distinct from nucleotide excision repair (NER), which deals with bulky adducts and helix distortions and leads to removal of an oligonucleotide of~28 bases and insertion of a correspondingly long repair patch. Defects in NER are known in humans, in the form of the rare genetic disease xeroderma pigmentosum, which is characterized by extreme sun sensitivity and skin cancer incidence (Wood, 1997) . It is notable that no corresponding diseases implicating BER have been described. Reactive oxygen is so pervasive that oxidative damage is inevitable and mutations that disable the repair pathway are likely to be lethal in embryo. Alternatively, backup pathways exist, so that oxidative damage is ultimately repaired and mutation has no major effect in terms of human disease.
8-Oxoguanine is removed from DNA in eukaryotes by the glycosylase OGG1 (Radicella et al., 1997; Roldán-Arjona et al., 1997; Rosenquist et al., 1997) . The enzyme has an associated lyase activity; the product of glycosylase action is held at the enzyme active site as a Schiff base which is prone to breakdown, leading to scission of the phosphodiester backbone (Dodson and Lloyd, 2002) . This is relatively slow and the enzyme AP endonuclease (APE1) can perform the breakage more quickly, releasing the glycosylase for further attack on other damaged bases. Thus APE1 stimulates OGG1 activity (Hill et al., 2001; Vidal et al., 2001) .
The ogg1 knockout mouse lacks OGG1 activity and yet accumulates oxidative DNA damage to only a small degree. It has a normal lifespan and is not cancer prone when compared with the wild-type (Klungland et al., 1999) . Removal of 8-oxoguanine does occur in cells cultured from the knockout mutant, but with a delay, indicating the existence of an alternative repair pathway (Klungland et al., 1999) .
The molecular epidemiological approach
The molecular epidemiological approach measures molecular biomarkers, usually in samples of blood, rather than simply looking at disease incidence. The biomarkers might represent exposure to disease-causing or protective agents, individual susceptibility or early stages in development of disease. Exposure to carcinogens can be assessed by measuring DNA damage, adducts covalently bound to albumin or urinary metabolites. In certain cases, the link between exposure and cancer may be strong enough that measurement of these biomarkers gives an indication of cancer risk; aflatoxin, a causative agent in liver cancer, is a notable example (Montesano et al., 1997) . However, in general, too many other steps intervene between DNA damage and carcinogenesis for there to be a clear link between markers of individual exposure and cancer risk. One of these steps, obviously, is DNA repair.
It is likely that in a human population there will be variations in BER, resulting from genetic polymorphisms and even gene deletions (if the alternative pathway theory is correct). Such genetic heterogeneity might be expected to lead to differences in the steady-state level of DNA damage, variations in cancer risk and even differential ageing, since one theory of ageing proposes the accumulation of oxidatively damaged biological molecules, including DNA, as the underlying cause. Berwick and Vineis (2000) have reviewed the many reports linking inadequate repair of oxidative DNA damage to an increased risk of cancer in man. These mostly take the form of case-control studies, i.e. they compare the repair capacity in lymphocytes from cancer patients with control cells from subjects not suffering from the disease. The matching of cases to controls is crucial, but frequently is not carefully performed. The assay for DNA repair in most common use is a very indirect one, based on the sensitivity of cells to a DNAdamaging agent, usually the radiomimetic chemical bleomycin; the end-point is generally chromosome breakage, which clearly could reflect factors other than DNA repair, including antioxidant protection and cell cycle kinetics.
In some studies, a more direct assay for DNA repair was employed. Jałoszyński et al. (1997) exposed lymphocytes from breast cancer patients and controls to bleomycin and assessed the ability to repair strand breaks on incubation for 0.5-1 h. Cancer patients typically showed lower repair rates. Schmezer et al. (2001) examined repair in stimulated lymphocytes from lung cancer patients and controls, treated with bleomycin. The rate of removal of damage in a 15 min incubation was significantly lower in lung cancer patients than in controls. A similar result was reported by Leprat et al. (1998) , who compared the capacity to repair radiation-induced DNA breaks in lymphocytes from patients who developed thyroid cancer as a consequence of radiotherapy for a previous cancer and from healthy controls.
An assay was developed in which the cells under study do not receive the damage directly, but are exposed to a damaged plasmid, introduced by transfection. The plasmid contains a reporter gene; if the damage is satisfactorily repaired, the reporter gene product is synthesized and its intensity or reactivity is taken to indicate repair capacity (Athas et al., 1991) . This approach has been applied principally to the examination of variations in NER, using plasmids damaged by UV light or a bulky adduct. Comparing basal cell carcinoma (skin cancer) patients and controls, risk of the disease was associated with reduced DNA repair capacity, although with borderline statistical significance (Wei et al., 1993) .
There is a potential problem with case-control studies, since, however good the matching, the cases are inevitably different from the controls because they have the disease and the parameter measured may be an effect rather than a cause of this condition. It is not unlikely that DNA repair, antioxidant capacity and cell proliferation may be altered as a result of cancer. In addition, as pointed out by Hemminki et al. (2000) , extrapolation from results obtained with lymphocytes to other tissues that are the real cancer target can be risky. Notwithstanding the serious reservations, these studies do consistently indicate a positive association between sensitivity to mutagens and cancer occurrence.
Genetic polymorphisms in human OGG1 (hOGG1) have been investigated for links with cancer. A polymorphism at 490 codon 326 gives rise to alternative Ser and Cys in the protein, and the Cys-containing protein was less able to suppress mutation in a bacterial complementation assay . The same group investigated the distribution of this polymorphism in gastric cancer cases and controls in Japan and found no difference . Further polymorphisms, located in the 5Ј-non-coding region, were identified (Ishida et al., 1999) ; a G→T transition at position -18 was significantly associated with risk of adenocarcinoma of the lung. Chevillard et al. (1998) found homozygous mutations in hOGG1 in one out of 15 human kidney carcinomas and in two of 25 small cell lung cancer samples. Normal tissue, available for the kidney sample, had a homozygous wild-type genotype. Probably the inactivation of OGG1 occurs during carcinogenesis by mutation in one allele and deletion of the other. Blons et al. (1999) found no evidence for an involvement of hOGG1 polymorphisms in head and neck carcinogenesis.
With the information from the human genome and, in particular, the analysis of single nucleotide polymorphisms (SNPs), there is ever-increasing interest in the genetic determinants of susceptibility to cancer and other diseases. The simplest approach to identifying links between genotype and cancer occurrence is to carry out case-control studies, but the problem of matching the control group to the cancer patients remains. A prospective study would be ideal. In this, the genetic data are collected from a suitable cohort (or, more simply, DNA samples are stored); at some time in the future, patients with disease are identified and matched with healthy controls from within the same cohort; a 'nested case-control' design. Genotypes in the two groups can then be compared without danger of selection bias. Polymorphisms are, by definition, genetic variants occurring in 1% or more of the population. Although some may occur at frequencies of~50%, they are typically much rarer, which means that large numbers of subjects must be screened to achieve statistically sound conclusions. Interactions between two (or more) gene products are often important, and investigating these at the level of genetic polymorphisms necessitates a further increase in numbers.
As Berwick and Vineis (2000) state at the end of their survey of 'repair' and cancer; 'It is not clear that conducting these [genotyping] studies without concomitant studies of expression and/or function will be fruitful'. Ideally, in a prospective study with nested case-control design at a later stage, the relevant phenotypic biomarkers should be measured at the time of sample collection, as it is unlikely that samples stored frozen for many years will be amenable to analysis. Simple, rapid and robust methods for biomarker measurement are therefore required. Given good functional assays for DNA damage and repair, an alliance with genotype analysis would allow us to answer crucial questions. 7. Does repair capacity decline with age? Do particular repair phenotypes or genotypes lead to accelerated ageing?
DNA repair assays
If we are to measure DNA repair function, what is the choice of assays? As well as being simple, robust and rapid, the assay should of course be relevant (it should measure repair of the lesion of interest, in this case oxidative base damage) and it should be well-characterized in terms of sensitivity, experimental reproducibility and inter-and intra-individual variation.
Unscheduled DNA synthesis (UDS)
UDS is a traditional assay for DNA repair (Lambert et al., 1979 ); incorporation of [ 3 H]thymidine into the DNA of cells treated with a genotoxic agent is measured in the absence of replication (either because cells are in a non-proliferating stage of the cell cycle or because replication is artificially inhibited). UDS is easily demonstrated after UV damage, but incorporation is very low during BER, since the gaps to be filled are far smaller. Even when testing for NER, the doses that must be used are close to the level that saturates the assay and above those that kill most cells (Hu et al., 1996) . If possible, for a valid DNA repair assay test doses of damage should be well below lethal doses and preferably close to the level likely to be encountered in life. UDS is clearly not suitable for assessing BER of oxidative damage.
Cellular repair
In the standard bleomycin sensitivity assay described earlier, the effect of repair is assessed by the number of chromatid breaks present. A more direct approach is to measure the DNA damage and monitor its removal. Probably the best, and certainly the most popular, method for measuring DNA breaks is the comet assay (single cell alkaline gel electrophoresis). The cells are embedded in agarose on a microscope slide and lysed in Triton X-100 and 2.5 M NaCl. This removes membranes, cytoplasm and most nuclear proteins, leaving the DNA as tightly packed supercoiled loops attached to the residual nuclear matrix in a nucleoid. The presence of breaks relaxes the supercoiling and on subsequent alkaline electrophoresis the relaxed loops are drawn out to form a 'comet' as viewed by fluorescence microscopy. The higher the break frequency, the more DNA is in the tail of the comet. This approach was used by Jałoszyński et al. (1997) , Leprat et al. (1998) and Schmezer et al. (2001) to follow the kinetics of rejoining of breaks. [Leprat et al. (1998) modified the normal procedure by embedding the cells in agarose and then incubating them for repair, rather than embedding them after repair incubation.] Repair of oxidized bases can also be followed with the comet assay. An additional step is introduced; after lysis, the nucleoids are incubated with a lesion-specific endonuclease which converts oxidized bases to breaks. Endonuclease III is specific for oxidized pyrimidines, while formamidopyrimidine DNA glycosylase (FPG, the bacterial counterpart of OGG1) recognizes altered purines, viz formamidopyrimidines and 8-oxoguanine. Lymphocytes repair 8-oxoguanine, introduced by treating the cells with the photosensitizer Ro 19-8022 and visible light, relatively quickly (Figure 1) . This approach to assessing repair has the advantage of sensitivity, so that the cellular response to low levels of damage can be assessed. However, the need to carry out prolonged incubations is a drawback. 
Host cell reactivation
Lymphocytes are transfected with a plasmid containing a reporter gene [e.g. the chloramphenical acetyltransferase (cat) gene or the gene for luciferase] which has been damaged, for instance with UV light or benzo[a]pyrene diol epoxide (both repaired by NER). The ability of the transfected cells to repair the gene is assessed by the restoration of activity of the reporter gene product. However, results may be influenced by the efficiency of transfection, and a wide inter-individual variation in DNA repair capacity is seen. The assay is cumbersome, and is mainly used by one group.
In vitro repair A more biochemical approach involves measurement of the repair capacity of a whole cell extract. In one version of this, the extract is incubated with an oligonucleotide containing one 8-oxoguanine residue and a terminal 32 P label (Roldán-Arjona et al., 1997) . The alteration in size on cleavage of the phosphodiester bond at the 8-oxoguanine is detected by conventional gel electrophoresis and visualization of the 32 P-labelled fragments. Alternatively, the extract is incubated with closed circular plasmid DNA containing specific damage (~1 lesion/ circle), and nicking of circles is detected by the change in electrophoretic migration. This method was developed by Redaelli et al. (1998) to estimate APE activity on a substrate with AP sites. In a further variation, Elliott et al. (2000) incubated plasmid DNA containing oxidative damage (introduced via hydroxyl radicals or singlet oxygen) with a cell-free extract of lymphocytes in the presence of deoxyribonucleoside triphosphates, one of which was labelled with 32 P. Thus they were able to measure the overall repair reaction, from incision to polymerization. The comet assay has also been adapted to measure in vitro repair . The damaged substrate comprises gel-embedded nucleoids from cells treated with Ro 19-8022 and light to induce 8-oxoguanine; they are incubated with extract from the cells of interest and the rate of incision is ascertained. This assay was validated using cell extract from an ogg1 knockout mouse cell line, which, in contrast to extract from wild-type cells, had no activity. 
Gene expression
Changes in the level of OGG1 mRNA are determined by semiquantitative RT-PCR, real time PCR or by hybridization with a cDNA or oligonucloeotide microarray.
Addressing some of the questions
What is the normal range of repair activities in healthy humans? Janssen et al. (2001) measured OGG1 activity in lymphocytes from 34 healthy individuals, using the 8-oxodG-oligonucleotide cleavage assay. Activities varied over a 2-fold range. We find a range of~3-fold using the in vitro test based on the comet assay ( Figure 2 and unpublished results). APE activity was assessed by Redaelli et al. (1998) ; the range in a group of 10 normal subjects was 2.5-fold. Variation of this order, whether it arises from genetic differences or is the result of environmental influences, is sufficient to have potential consequences for health. However, the variation could simply represent experimental variation or ill-defined fluctuations. How stable is individual repair capacity? Figure 2 shows the OGG1 activity measured in lymphocyte samples taken from our 14 volunteers on two occasions, 5 weeks apart. The strong correlation indicates that, at least in the short term, the potential for repair is stable. Intra-individual variation is far less than inter-individual variation.
Do differences in repair capacity correlate with any genetic variations?
The relative inefficiency of the OGG1 protein with Cys326 compared with Ser326 in the bacterial complementation assay has been mentioned already. In Europeans, the polymorphism occurs with allele frequencies of 75% for Ser326 and 25% for Cys326, but it does not result in altered OGG1 activity in the plasmid cleavage assay (Janssen et al., 2001) . Does repair capacity decline with age? Are there differences between men and women? Janssen et al. (2001) found no difference between men and women in lymphocyte OGG1 activity and no influence of 492 smoking habit. An early study of NER (Lambert et al., 1979) found a decrease of 30% in UV-induced repair synthesis between the ages of 20 and 90 and a decline of 0.6% per year was reported by Moriwaki et al. (1996) using the plasmid host cell reactivation assay. Barnett and King (1995) used the comet assay to measure DNA strand breaks in lymphocytes immediately after H 2 O 2 treatment and after incubation for 90 min. Lymphocytes from 65-69 year olds had significantly more residual breaks at that time than did lymphocytes from 35-39 year olds. However, in a recent investigation of lymphocytes from 226 subjects aged between 21 and 88 we saw no effect of age on the ability to nick 8-oxoguaninecontaining nucleoids in the in vitro comet assay (Harrington et al., unpublished results) . Animal studies may be informative, although ageing in rodents (lifespan~2 years) is arguably not comparable with ageing in man. In an in vitro plasmid-nicking assay, nuclear OGG1 activity from mouse liver decreased slightly with age, while mitochondrial OGG1 actually increased significantly (de Souza-Pinto et al., 2001) How important is DNA repair rate in determining the steady-state level of damage? It may seem intuitively obvious that a high repair rate will lead to a decrease in the steady-state level of damage. However, we do not know enough about the regulation of repair. An alternative model is that the more reactive oxygen there is, the more repair is induced and, in consequence, the steadystate level of damage is kept constant, in which case no correlation between damage and repair would be expected. Analysis of repair rates and damage levels would help to decide between these possibilities, but the data are not yet available.
Is repair modulated by environmental factors? Is it induced by damage or enhanced by dietary factors?
There are some relevant reports of studies with animals and cultured cells. Kim et al. (2001) exposed pulmonary type IIlike epithelial cells to crocidolite asbestos; repair activity (on an oligonucleotide containing 8-oxoguanine) and hOGG1 mRNA expression increased significantly. A similar effect of asbestos on OGG1 was seen in hamster and rat lungs (Yamaguchi et al., 1999) and in rats exposed by intra-tracheal instillation to diesel exhaust particles, the level of 8-oxoguanine in DNA showed an increase, followed by an increase in repair activity and induction of OGG1 mRNA synthesis . Cherng et al. (2002) found an induction of OGG1 mRNA expression in lung adenocarcinoma CL3 cells by H 2 O 2 and cooking oil fumes, and in a group of cooks and housewives exposed to these fumes hOGG1 mRNA expression was also higher relative to an unexposed control group. Janssen et al. (2001) quote unpublished data showing a significant decrease in OGG1 activity in workers exposed to metal dust. Turning to presumably beneficial effects related to nutrition, Tomasetti et al. (2001) found that supplementation with coenzyme Q 10 enhanced in vitro repair of 8-oxoguanine by lymphocyte extract and we have recently demonstrated an enhancement of repair by consumption of fruit (Collins et al., in preparation) .
Conclusions
Is low repair capacity associated with high risk of cancer? In our view, with the limitations of the case-control studies so far undertaken, this is still an open question, which can be answered only by a large-scale prospective study. Repair rates should be measured and genotypes analysed and then over the ensuing years cancer incidence recorded. To our knowledge, no such study has yet been undertaken. Even with this approach, there is an underlying assumption that lymphocytes are a representative cell type to tell us about repair capacity in the body as a whole, and this assumption is hard to test in humans.
